STOCKHOLM (EGMN) - Adding the investigational drug iniparib to a gemcitabine and cisplatin doublet failed to improve outcomes significantly in a phase II study of 119 patients with advanced non-small-cell lung cancer.The disappointing result follows a phase III trial in which iniparib failed to confirm survival gains when added to gemcitabine (Gemzar) and carboplatin chemotherapy in patients with metastatic triple-negative...